Weekly Top News – Psoriasis – September 9, 2019

September 9, 2019

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi for the treatment of moderate to severe plaque psoriasis in adults is included in the high-cost protection and is available in Sweden [Google Translation] (Mynewsdesk) – Sep 6, 2019 – “Skyrizi (risankizumab) is part of the drug subsidy in Sweden from June 14, 2019 and is now available at Swedish pharmacies….According to a decision from the Dental Care and Medicines Benefit Agency (TLV), Skyrizi (risankizumab) is included in the Swedish drug benefit. Skyrizi has already been approved in Europe for the treatment of moderate to severe plaque psoriasis in adults who need systemic treatment.”

 

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Almirall launches ‘Ilumetri’ in Spain for moderate to severe plaque psoriasis in adults [Google Translation] (Infosalus.com) – Sep 2, 2019 – “The pharmaceutical company Almirall has started the commercialization in Spain of ‘Ilumetri’ (tildrakizumab) for the treatment of moderate to severe plaque psoriasis in adults, after receiving the marketing authorization from the European Commission in September 2018 and the decision of the Ministry of Health to include it in the pharmaceutical benefit of the National Health System (SNS) last July.”

 

Cosentyx (secukinumab) / Novartis
Cosentyx regulatory estimate: Approval in axial spondyloarthritis in H2 2020 (Jefferies) – Sep 7, 2019 – A subscription to Thomson ONE is required to gain full access to report 67891655; Page no: 4; REPORT TITLE: “Novartis AG: Wave of new launches underappreciated driving confidence in ongoing upgrades”; AUTHOR: Welford, Peter, et al; DATE: 08/30/2019

No Comments

Post a Comment

Comment
Name
Email
Website